RedHill Biopharma Ltd.
RDHL
$1.64
-$0.09-5.20%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 58.59% | 58.59% | 382.03% | 382.03% | -28.40% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 58.59% | 58.59% | 382.03% | 382.03% | -28.40% |
| Cost of Revenue | 14.46% | 14.46% | 71.76% | 71.76% | -12.90% |
| Gross Profit | 111.64% | 111.64% | 3,818.09% | 3,818.09% | -41.01% |
| SG&A Expenses | -34.29% | -34.29% | -45.37% | -45.37% | -44.44% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -23.26% | -23.26% | -29.59% | -29.59% | -11.19% |
| Operating Income | 48.18% | 48.18% | 68.39% | 68.39% | 4.17% |
| Income Before Tax | -33.84% | -33.84% | 80.88% | 80.88% | -302.89% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -33.84% | -33.84% | 80.88% | 80.88% | -302.89% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -33.84% | -33.84% | 80.88% | 80.88% | -302.89% |
| EBIT | 48.18% | 48.18% | 68.39% | 68.39% | 4.17% |
| EBITDA | 47.57% | 47.57% | 67.84% | 67.77% | -11.05% |
| EPS Basic | 12.70% | 12.70% | 94.20% | 94.20% | -122.05% |
| Normalized Basic EPS | 12.70% | 12.70% | 96.66% | 96.66% | 99.15% |
| EPS Diluted | 12.70% | 12.70% | 94.20% | 94.20% | -122.05% |
| Normalized Diluted EPS | 12.70% | 12.70% | 96.66% | 96.66% | 99.15% |
| Average Basic Shares Outstanding | 53.32% | 53.32% | 229.96% | 229.96% | 820.19% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |